We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
脑瘫伴癫痫患儿合理用药研究.
- Authors
肖佳佳; 李唤星; 范媛媛; 李 燕
- Abstract
Objective To analyze the use of oral antiepileptic drugs(AEDs) in children with cerebral palsy and epilepsy in our hospital,and to promote the rational use of AEDs in our hospital. Methods A retrospective analysis was made in 136 inpatients diagnosed with cerebral palsy and epilepsy from January 2016 to December 2017 in the first and second wards of pediatric and pediatric rehabilitation department of our hospital. The drug use,clinical efficacy,seizure frequency and rationality were analyzed. Results The top four AEDs were sodium valproate oral solution (VPA), levetiracetam oral solution (LEV), oxcarbazepine suspension solution (OXC) and topiramate capsule (TPM), of which 1 1 were over-prescribed(2 were over-age and 9 were over-dosage). Boys were 1. 96 times as many as girls, and 123 cases (90. 44%) of 7-year-old preschool epilepsy seizures occurred. Single drug treatment accounted for 63.97%, which was the main treatment method; VPA + LEV was the main combination use of drug, accounting for 16. 91% of the total number; triple drug use was less, only 8 cases, accounting for 5. 88% of the total number, all of which were diagnosed as intractable epilepsy. Conclusion The use of ADEs in children with cerebral palsy complicated by epilepsy in our hospital is mostly reasonable, but there are still cases of over-prescribed drug use, so we should standardize the over-prescribed drug use behavior. At the same lime, we should pay attention to the interaction among AEDs and between AEDs and other drugs,and pay more attention to the children with intractable epilepsy,and adjust them according to their personal conditions. The dosage of AEDs and the blood concentration of AEDs should be monitored when necessary.
- Publication
Practical Pharmacy & Clinical Remedies, 2019, Vol 22, Issue 9, p972
- ISSN
1673-0070
- Publication type
Article
- DOI
10.14053/j.cnki.ppcr.201909017